MZT Holdings Inc.

MZT Holdings Inc. and Sysmex Corp. announced that they have formed a partnership to develop an automated Pap smear test. This new approach will use Sysmex's flow cytometry technology and Matritech's patented NMP179 protein biomarker to perform highly accurate cell-by-cell analysis for cervical cancer.